Sanofi-Aventis

In 2000 the foundation was renamed the Aventis Foundation subsequent to the 1999 merger of Hoechst and Rhône-Poulenc. DeBusschere died of a heart attack in New York, 2003. The Aventis Prizes are managed by the Royal Society, the UK national academy of science, and the Aventis Foundation, a German charitable trust established in 1996 as the Hoechst Foundation with an endowment of €50 million. He also was a pitcher in Major League Baseball with the Chicago White Sox in 1962-63. The Aventis Prizes for Science Books, which celebrate the very best in popular science writing for adults and children, have grown to be one of the world's most prestigious non-fiction literary prizes. At the age 24, he was assigned the position of player-coach and thus became the youngest ever coach in league history. Research and development investment was €4 bn. His #22 jersey was retired by the Knicks, but not until many years after his retirement; it is thought the delay was due to DeBusschere's taking a front-office job with the rival New Jersey Nets upon his retirement.

It has operations in more than 100 countries throughout the 5 continents and has 99,700 employees worlwide. DeBusschere was named to the Hall of Fame after a 12-year career in which he averaged 16.1 points and eleven rebounds while being named to eight NBA All-Star Teams. In 2003, Sanofi-Aventis's consolidated sales was €25 bn. He was the youngest coach in NBA history. Dehecq has been the General Manager of Sanofi since its creation in 1973. He was drafted by the Detroit Pistons in 1962 and won two championships with the New York Knicks. The merged company was based in Strasbourg, France. David Albert DeBusschere (October 16, 1940 - May 14, 2003 in Detroit, Michigan) was a professional basketball player.

merged with Hoechst Marion Roussel, in turn formed merging Hoechst AG with Roussel and Marion Merrell Dow. Aventis was formed in 1999 when Rhône-Poulenc S.A. The merged company was based in Paris, France. Sanofi-Synthélabo was formed in 1999 when Sanofi merged with Synthélabo.

French government, desiring a local merger solution, put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running. Government intervention also played an active role. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 bn in place of the previously rejected hostile bid. Initially, Aventis rejected the bid because it offered inferior value based on the company's share value.

In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 bn against Aventis. Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo merged with Aventis. . Sanofi-Aventis covers 7 therapeutic areas: cardiovascular, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines.

Sanofi-Aventis engages in the research, development, manufacture and marketing of pharmaceutical products for sale principlally in the presciption market. Sanofi-Aventis (Euronext:FR0000120578) (NYSE:SNY), headquartered in Paris, France, is the world's number 3 company in the pharmaceutical industry (behind Pfizer and GlaxoSmithKline, but above Merck and AstraZeneca). Yahoo! - Sanofi-Aventis Company Profile. Sales by geographic area breakdown: 58% from Europe, 24% from US, 18% from rest of the world.

Sales by activity breakdown: 39% from Cardiovascular/Thrombosis, 29% from Central Nervous System, 18% from Internal Medicine, 11% from Oncology, 3% from other pharmaceutical products. Voting right distribution: 21.37% to Total, 17.12% to L'Oréal, 1.54% to employees, and 59.97% to the public. Breakdown of share ownership: 12.65% by Total SA, 10.13% by L'Oréal, 5.47% treasury shares, 1.29% employees, the remaining 70.46% are publicly traded. Gérard Le Fur, Senior EVP.

Jean-François Dehecq, Chairman and CEO.